Systematic Evaluation of Antibody-Antigen Interactions for Suitability in Immunoassays Using Parallel Microarray ELISA

M. Coolen, K. M. van Ham, T. J. Schulte, G. Schilders. Future Diagnostics, Wijchen, Netherlands

Background

Each immunoassay has unique specifications that are largely affected by the used capture & detection molecules / antibodies:

- specificity
- sensitivity
- dynamic range
- robustness
- speed of interaction
- strength of interaction
- matrix compatibility

Direct testing of all capture & detection molecule combinations and parameters in the final assay configuration is often not possible: time-, material-& budget-constraints. Theoretical $K_{on}/K_{off}/K_{D}$ determinations are costly and have only limited translatability to the end format.

Needed:


Method to systematically compare capture & detection molecule options for their desired specifications and under realistic assay conditions

Approach

Results:

100.00

80.00



Parallel microarray ELISA

HBsAg: Capture Ab binding kinetics

HBsAg: Capture Ab sensitivity

....

....

.... ...

—Ab2 —Ab3 —Ab4

[HBsAg] in IU/mL

.....

....

Ab3 [analyte]

Ab4 [analyte]

----[low] — [high] — — [mid] -----[low]


——[high] — — [mid] ----- [low]

Kinetics & Sensitivity

Ab2 [analyte]

-[high] — — [mid] -


Results:



Legend: same Ab as capture & detection **Capture Ab mixes**

No analyte:

Capture Abs each spotted in a 3x3 grid at 3 concentrations. Different detection Abs per well. Green numbered boxes indicate same Ab as capture & detection. Blue box shows capture Ab mixes.



Heatmap of signal intensities from all options from analyte dilutions. High = purple; low = green. Blue boxes indicate antibody mixes.


Other observations:

- Marked performance differences in different sample matrices
- Sample cohort screen to identify Ab pair with best clinical performance (unique epitope/conformation/modifications)
- Sensitivity down to 0.01 IU/mL (~40 pg/mL)
- Serotype reactivity confirmation (Adw/Ayw)

Results:


micro-SC \





Strong synergistic effect observed when specific monoclonal antibodies were combined in the capture mix, resulting in a ~6-fold sensitivity enhancement compared to their separate performances.

Elevated binding potential and strength for antibodies with non-overlapping epitopes:




Note: Synergistic performance also observable at detection site of assay

Conclusions

- Parallel microarray ELISA evaluation of antibody-antigen interactions & antibody pairs is a robust and reliable method for identifying the best antibodies for an immunoassay.
- It allows for a systematic and quantitative screen of dozens of antibody options within 1-2 weeks under real immunoassay conditions using nanoliter spot volumes.
- This method has shown to be highly translatable and is customizable to accommodate diverse assay specifications.

Method

nano-liter dispensing



microarray ELISA inside each well

> 121 spots/well

80000 00000


> 11,000 data points per plate




ELISA-based toolbox to address required

- Time courses
- Buffer challenges


Parallel microarray ELISA





specifications

- Serial dilutions
- Interferent spikes





provincie

The Netherlands

The Netherlands